Mid Pharma Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

Celgene
$3,000.00
PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
March 29, 2018
More information
AbbVie
$3,000.00
PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2017–27.
February 28, 2018
More information
Acorda Company Analysis
$3,000.00
PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
February 9, 2018
More information
BioMarin Company Analysis
$3,000.00
PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
January 4, 2018
More information
Incyte Company Analysis
$3,000.00
PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
January 4, 2018
More information
Allergan
$3,000.00
Updated analysis and forecasts based on Q3 2017 company-reported sales.
December 12, 2017
More information
Merck KGaA Company Analysis
$3,000.00
PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
December 6, 2017
More information
Gilead Company Analysis
$3,000.00
Analysis of Gilead’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 21, 2017
More information
UCB Company Analysis
$3,000.00
PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
October 30, 2017
More information
Biogen
$3,000.00
PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2017–27
March 7, 2017
More information
Actelion
$3,000.00
Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
More information
Mid Pharma Outlook
$3,000.00
Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
More information
Lundbeck Company Analysis
$3,000.00
Description

Analysis of Lundbeck’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
September 27, 2016
More information

Mid Pharma

Mid Pharma

Celgene

AbbVie

Acorda Company Analysis

BioMarin Company Analysis

Incyte Company Analysis

Allergan

Merck KGaA Company Analysis

Gilead Company Analysis

UCB Company Analysis

Biogen

Actelion

Mid Pharma Outlook

Lundbeck Company Analysis